39 related articles for article (PubMed ID: 27037775)
1. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases.
Mohammed S; Shamseddine AA; Newcomb B; Chavez RS; Panzner TD; Lee AH; Canals D; Okeoma CM; Clarke CJ; Hannun YA
Breast Cancer Res; 2021 Jul; 23(1):76. PubMed ID: 34315513
[TBL] [Abstract][Full Text] [Related]
2. Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma.
Bailey KM; Airik M; Krook MA; Pedersen EA; Lawlor ER
Neoplasia; 2016 Aug; 18(8):480-8. PubMed ID: 27566104
[TBL] [Abstract][Full Text] [Related]
3. Effective combination of cold physical plasma and chemotherapy against Ewing sarcoma cells in vitro.
Nitsch A; Qarqash S; Römer S; Schoon J; Singer D; Bekeschus S; Ekkernkamp A; Wassilew GI; Tzvetkov MV; Haralambiev L
Sci Rep; 2024 Mar; 14(1):6505. PubMed ID: 38499701
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.
Balaraman K; Deniz E; Nelson E; Pilicer SL; Atasoy S; Molotkova A; Sevim H; Tiwari PB; Üren A; Wolf C
Eur J Med Chem; 2023 May; 251():115244. PubMed ID: 36917882
[TBL] [Abstract][Full Text] [Related]
5. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.
Zhang N; Liu H; Yue G; Zhang Y; You J; Wang H
PLoS One; 2016; 11(4):e0153546. PubMed ID: 27077911
[TBL] [Abstract][Full Text] [Related]
6. Revisiting 'Hallmarks of Cancer' In Sarcomas.
Honoki K; Tsujiuchi T; Kishi S; Kuniyasu H
J Cancer; 2024; 15(7):1786-1804. PubMed ID: 38434982
[TBL] [Abstract][Full Text] [Related]
7. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E; Chun KS; Kim DH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship.
Ceranski AK; Carreño-Gonzalez MJ; Ehlers AC; Colombo MV; Cidre-Aranaz F; Grünewald TGP
Mol Cancer; 2023 Mar; 22(1):49. PubMed ID: 36915100
[TBL] [Abstract][Full Text] [Related]
9. Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma.
van Erp AEM; Hillebrandt-Roeffen MHS; van Bree NFHN; Plüm TA; Flucke UE; Desar IME; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH
Sarcoma; 2022; 2022():3089424. PubMed ID: 35655525
[TBL] [Abstract][Full Text] [Related]
10. HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
Wu Y; Guo Q; Ju X; Hu Z; Xia L; Deng Y; Zhao P; Zhang M; Shao Y; Huang S; He X; Wen H; Wu X
Oncogene; 2021 Jul; 40(29):4770-4782. PubMed ID: 34148056
[TBL] [Abstract][Full Text] [Related]
11. Precision Oncology in Sarcomas: Divide and Conquer.
Carmagnani Pestana R; Groisberg R; Roszik J; Subbiah V
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914012
[TBL] [Abstract][Full Text] [Related]
12. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma.
Jin W
Front Cell Dev Biol; 2020; 8():613. PubMed ID: 32754598
[TBL] [Abstract][Full Text] [Related]
13. Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade.
Indovina P; Forte IM; Pentimalli F; Giordano A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664483
[No Abstract] [Full Text] [Related]
14. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.
Kovar H; Bierbaumer L; Radic-Sarikas B
Cells; 2020 Apr; 9(4):. PubMed ID: 32326412
[TBL] [Abstract][Full Text] [Related]
15. A biosystems approach to identify the molecular signaling mechanisms of TMEM30A during tumor migration.
Wang J; Wang Q; Lu D; Zhou F; Wang D; Feng R; Wang K; Molday R; Xie J; Wen T
PLoS One; 2017; 12(6):e0179900. PubMed ID: 28640862
[TBL] [Abstract][Full Text] [Related]
16. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
[TBL] [Abstract][Full Text] [Related]
17. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
[TBL] [Abstract][Full Text] [Related]
18. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Casini N; Forte IM; Mastrogiovanni G; Pentimalli F; Angelucci A; Festuccia C; Tomei V; Ceccherini E; Di Marzo D; Schenone S; Botta M; Giordano A; Indovina P
Oncotarget; 2015 May; 6(14):12421-35. PubMed ID: 25762618
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
